Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vir Biotechnology Inc V.VIR


Primary Symbol: VIR

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.


NDAQ:VIR - Post by User

Comment by Motherlode5155on Oct 04, 2018 11:24am
47 Views
Post# 28744745

RE:RE:RE:does any know re - Health Canada

RE:RE:RE:does any know re - Health Canada For one, they have the lowest valuation for a company with both license to grow and sell.  I recently toured their facility and was impressed.  They have a 10 acre land with option to expand to adjacent property.  Their first 84000sqft green house will be completed in early spring with annual output of 8000-9000 Kg per year.  They are able to grow at $1 per gram.  They are selling their product for 3-7$ per gram.  Their net profit is  potentially $16 mil- 54 mil!  This is not including their partnership deals in Quebec, and they probably are working on many other deal like this.  I did my due diligence with is stock.  The only reason why this stock is not trading at 5-10$ range is because they haven’t hyped it up, but it’s only matter of time before it gets noticed.  There is not much shares to buy out there because the insiders are  probably hoarding it for themselves.  I have been Taking profit from my other weed stocks and buying as many shares of Viridium as possible.  
<< Previous
Bullboard Posts
Next >>